Market Overview

Chembio Diagnostics Announces FDA Approval for DPP Point-of-Care HIV 1/2 Rapidi Test

Share:
Related CEMI
18 Biggest Mid-Day Gainers For Thursday
Mid-Afternoon Market Update: Dow Slides Over 100 Points; Sprint Shares Climb Following Q1 Results
Wall Street Breakfast: Apple Slammed In EU Tax Crackdown (Seeking Alpha)

Chembio Diagnostics, Inc. (Nasdaq: CEMI),a leader in point-of-care diagnostic tests for infectious diseases, announces receipt of approval from the U.S. Food and Drug Administration (FDA) to market the Company's Dual Path Platform^® (DPP^®) HIV 1/2 assay for the rapid, point-of-care (POC) detection of HIV-1/2 antibodies in either oral fluid or blood samples. This determination follows a review of Chembio's Premarket Approval (PMA) application and marks the first FDA approval of a diagnostic assay utilizing the Company's patented Dual Path Platform^® technology. DPP^® enables samples to bind directly with target analytes before detection reagents are introduced to visualize the test results, and can improve accuracy compared with the current lateral flow HIV test technologies.

Posted-In: News FDA

 

Related Articles (CEMI)

View Comments and Join the Discussion!